Live Updates > Live Update Details
2025-07-29 17:14:07
[Innovative drug of Changchun High-Tech's subsidiary is approved for marketing by FDA] ⑴Changchun High-Tech (000661.SZ) announced that the lyophilized powder for oral solution of amlodipine besylate developed by its holding subsidiary Brillian Pharma INC. has been approved for marketing by the FDA. ⑵This product is suitable for the treatment of hypertension, chronic stable angina, vasospastic angina and coronary heart disease confirmed by angiography in adults and patients aged 6 years and above. ⑶As an improved innovative drug of 505B2, this product is specially designed for children and patients with dysphagia, and can reduce the risk of cardiovascular events. ⑷This approval will enrich Brillian Pharma's product layout in the US market and enhance the competitiveness of the company's pharmaceutical business.
